GEMoaB aspires to become a leading, fully integrated biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of next generation immunotherapies for patients in underserved cancer indications.
We are hiring!
GEMoaB develops next generation immunotherapies against hard-to-treat blood and solid tumor cancers
–
GEMoaB GmbH is a privately-owned, clinical-stage biopharmaceutical company based in Dresden, Germany. GEMoaB has a broad pipeline of next generation immunotherapy product candidates in pre-clinical and clinical development for the treatment of hematological malignancies as well as solid tumors.
We are a passionate team of innovative scientists and clinical experts who thrive to push forward the boundaries of modern cancer therapy.
Fully addressing the limitations of current T-Cell-based immunotherapies through our proprietary next generation UniCAR, RevCAR & ATAC platforms.
Broad pre-clinical and clinical stage pipeline with four assets planned to be in clinical development in solid tumors and hematological malignancies by mid of 2020.
Preferred manufacturing partnership with our sister company Cellex in Cologne, a world leader in producing hematopoietic blood stem cell products and a leading European CMO for CAR-T cells.
